Aspen Offers Commitments To Settle EU Price Gouging Claims
Three-Year Investigation Would Close If Company Suggestions Adopted
After the European Commission adopted a preliminary assessment that Aspen Pharmacare “may have abused its dominant position by imposing unfair prices” for six mature oncology brands, the South African firm has outlined multiple commitments that would bring to a close a three-year Commission investigation across the EEA if adopted.
